Peeling The Layers Back on Valuation For Sarepta Therapeutics, Inc. (NasdaqGS:SRPT)

Developed by James O’Shaughnessy, the Value Composite score uses six valuation ratios. These ratios are price to earnings, price to cash flow, EBITDA to EV, price to book value, price to sales and shareholder yield.  Sarepta Therapeutics, Inc. (NasdaqGS:SRPT) has a Value Composite score of 93. The VC score is displayed as a number between 1 and 100. In general, a company with a score closer to 0 would be seen as undervalued, and a score closer to 100 would indicate an overvalued company. Removing the sixth ratio (shareholder yield) we can view the Value Composite 1 score which is currently sitting at 91.

Investors are typically trying to find solid stocks to add to the portfolio. When it comes to stock picking, there is no magic formula. There are various techniques that may provide better outcomes than others, but it’s how these techniques are put together and applied that can make all the difference. One of the keys to successful investing is the proper use of information. Everyone can see the vast amount of data that is available on publically traded companies. Being able to interpret the data could end up being the most important factor when it comes to successfully selecting stocks to buy. Taking the time to investigate a particular stock that looks attractive can be a smart move. Investors may be better served to not just jump on the hot stock of the day, but employ analysis that may help uncover some buried information. Good stocks are indeed out there, it may just take some time to figure out which ones they are.

We can now take a quick look at some historical stock price index data. Sarepta Therapeutics, Inc. (NasdaqGS:SRPT) presently has a 10 month price index of 1.20021. The price index is calculated by dividing the current share price by the share price ten months ago. A ratio over one indicates an increase in share price over the period. A ratio lower than one shows that the price has decreased over that time period. Looking at some alternate time periods, the 12 month price index is 1.58394, the 24 month is 1.33392, and the 36 month is 1.96365. Narrowing in a bit closer, the 5 month price index is 1.57679, the 3 month is 1.43835, and the 1 month is currently 1.17291.

Watching some historical volatility numbers on shares of Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), we can see that the 12 month volatility is presently 92.385800. The 6 month volatility is 50.721400, and the 3 month is spotted at 56.875100. Following volatility data can help measure how much the stock price has fluctuated over the specified time period. Although past volatility action may help project future stock volatility, it may also be vastly different when taking into account other factors that may be driving price action during the measured time period. 

Valuation Scores

Shifting gears, we can see that Sarepta Therapeutics, Inc. (NasdaqGS:SRPT) has a Q.i. Value of 77.00000. The Q.i. Value ranks companies using four ratios. These ratios consist of EBITDA Yield, FCF Yield, Liquidity, and Earnings Yield. The purpose of the Q.i. Value is to help identify companies that are the most undervalued. Typically, the lower the value, the more undervalued the company tends to be.

At the time of writing, Sarepta Therapeutics, Inc. (NasdaqGS:SRPT) has a Piotroski F-Score of 5. The F-Score may help discover companies with strengthening balance sheets. The score may also be used to spot the weak performers. Joseph Piotroski developed the F-Score which employs nine different variables based on the company financial statement. A single point is assigned to each test that a stock passes. Typically, a stock scoring an 8 or 9 would be seen as strong. On the other end, a stock with a score from 0-2 would be viewed as weak.

Sarepta Therapeutics, Inc. has an M-score Beneish of 4739049.551573. This M-score model was developed by Messod Beneish in order to detect manipulation of financial statements. The score uses a combination of eight different variables. The specifics of the variables and formula can be found in the Beneish paper “The Detection of Earnings Manipulation”.

Investors may be interested in viewing the Gross Margin score on shares of Sarepta Therapeutics, Inc. (NasdaqGS:SRPT). The name currently has a score of 63.00000. This score is derived from the Gross Margin (Marx) stability and growth over the previous eight years. The Gross Margin score lands on a scale from 1 to 100 where a score of 1 would be considered positive, and a score of 100 would be seen as negative.

Sarepta Therapeutics, Inc. (NasdaqGS:SRPT) has a current MF Rank of 14411. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to spot high quality companies that are trading at an attractive price. The formula uses ROIC and earnings yield ratios to find quality, undervalued stocks. In general, companies with the lowest combined rank may be the higher quality picks. Sarepta Therapeutics, Inc. has a current ERP5 Rank of 15115. The ERP5 Rank may assist investors with spotting companies that are undervalued. This ranking uses four ratios. These ratios are Earnings Yield, ROIC, Price to Book, and 5 year average ROIC. When looking at the ERP5 ranking, it is generally considered the lower the value, the better.

Leave a Comment